Table 2 Clinical characteristics of patient cohort
From: Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy
Characteristic | PSA bounce | No bounce | P value |
|---|---|---|---|
Patients (n) | 40 | 23 | |
Age (years) | 65 (48–79) | 69 (58–81) | 0.01 |
Follow-up (days) | 1432 (825–2579) | 1273 (962–2428) | 0.06 |
Gleason score | |||
<7 | 30 | 12 | 0.1 |
=7 | 10 | 11 | |
Tumour stage | |||
⩽1c | 14 | 5 | 0.39 |
⩾2a | 26 | 18 | |
Radiation dose (P-D90) | 189 (152–260) | 190 (140–233) | 0.37 |
Prostate volume (cm3) | 24.3 (14.4–35.1) | 25.0 (17.4–35.3) | 0.64 |
Rad dose/prostate volume | 7.58 (5.29–13.75) | 7.52 (4.85–9.84) | 0.23 |
Pre-therapy PSA (ng ml−1) | 7.58 (2.3–10.9) | 5.23 (2.6–21.0) | 0.2 |
Decrease in PSA at first follow-up | 0.24 (−2.11–0.81) | 0.48 (−0.96–0.76) | 0.04 |
